Last checked at 29 Jul 2019 16:29
(AIM: SAR) | 29 July 2019 |
Sareum Holdings plc
("Sareum" or "the Company")
Additional disclosure concerning Michael Owen
Sareum Holdings PLC, the specialist small molecule drug development business, announced on 13 November 2018 the appointment of Michael Owen as a Non-Executive Director of the Company.
It has come to Sareum's attention that whilst his former directorship of BliNK Biomedical SAS ("BliNK") was detailed in that announcement, his former directorship of BliNK's subsidiary Blink Therapeutics Limited during the five years prior to that announcement should also have been included.
For further information, please contact:
Sareum Holdings plc |
|
Tim Mitchell | 01223 497 700 |
WH Ireland Limited (Nominated Adviser) | |
Chris Fielding / James Sinclair-Ford | 020 7220 1666 |
Hybridan LLP (Nominated Broker) |
|
Claire Noyce | 020 3764 2341 |
Citigate Dewe Rogerson (Media enquiries) |
|
Shabnam Bashir/ Mark Swallow/ David Dible | 020 7638 9571 |
- Ends -